Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Sagimet Biosciences Inc. (SGMT) is a Biotechnology company based in US with a market capitalization of $230.4M. Free cash flow was negative at -$45.7M. This page tracks SGMT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 14 employees · IPO Jul 17, 2023
Valuation
Valuation & price
$6.90as of May 17, 2026· -32.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.07
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$230.4M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$45.7M
Free cash flow (USD)
-$113M
Net debt
Net cash position
3.2%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 22, 2026Filing
Insider Sell $141K · 10b5-1 PlanKemble George · Director · $140.5K
- Insider sellJul 22, 2026Filing
Insider Sell $82KRozek Elizabeth · Chief Legal & Admin. Officer · $81.8K
- Insider sellJul 22, 2026Filing
Insider Sell $497KHappel David · Director, President & CEO · $497.1K
- 8-K eventJul 20, 2026Filing
Clinical Development Update
- 8-K eventJun 12, 2026Filing
Board Resignation and Election
- 8-K eventJun 3, 2026Filing
Performance-Based Stock Units Award
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventMay 12, 2026Filing
Financial Results Reported
- 8-K eventApr 28, 2026Filing
Stock Offering
- 8-K eventApr 27, 2026Filing
Clinical Trial Updates
Questions
Frequently asked questions
What is Sagimet Biosciences Inc.'s market cap?
Sagimet Biosciences Inc. (SGMT) has a market capitalization of $230.4M.
What is SGMT's P/E ratio?
A meaningful P/E ratio is not available for SGMT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is SGMT's price-to-book (P/B) ratio?
SGMT trades at 2.07 times book value per share.
Are insiders buying SGMT stock?
SEC Form 4 filings show no open-market insider buys at Sagimet Biosciences Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.